In addition, we have discovered a number of candidate markers that have generally low incidence in breast cancer but have potential therapeutic value, including genetic aberrations in KRAS, ROS1, ALK, MET, NTRK, and EGFR. Certain mutations in these genes are associated with response to targeted therapy in other cancer types, but their therapeutic value in breast cancer requires further evaluation. This evidence concerns the gene MET and breast cancer.